Areas of Interest & Competitive Research Grants
Areas of Interest (AOI)
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| CV-Mavacamten -2023_RFP_Cycle_1 | 18-May-23 | 30-May-23 | 20-Jul-23 |
| Immunology – Zeposia UC (Ozanimod) | 20-Mar-23 | 08-May-23 | 25-May-23 |
| Immunology – Zeposia MS (Ozanimod) | 30-Jun-23 | 10-Jul-23 | 27-Jul-23 |
CV-Mavacamten - 2023_RFP_Cycle_1
Obstructive HCM diagnosis and management
In Scope:
- Earlier diagnostic approach to the at-risk population
- Diagnosis and monitoring of HCM progression
- Monitoring may include:
- Biomarkers, imaging, and correlation with clinical and trial endpoints.
*Interventional and observational projects are acceptable, including new approaches to real-world data.
Out of Scope:
Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.
The Impact of CAMZYOS on Pathophysiology and disease progression
In Scope:
- Special interest in the following:
- Arrhythmias (Atrial & Ventricular)
- Cardiac structure (strain, energetics, etc.)
- Additional complications from the disease
*Interventional and observational projects are acceptable, including new approaches to real-world data.
Out of Scope:
Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.
CAMZYOS echo monitoring.
In Scope:
- Assess the benefits of innovative Echo technology in diagnosis, monitoring, workflow, access, coordination of care, and health equity in correlation with CAMZYOS label
*Interventional and observational projects are acceptable, including new approaches to real-world data.
Out of Scope:
Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.
Clinical use of CAMZYOS
In Scope:
- In special populations (minorities, elderly, comorbidities)
- CAMZYOS use in patients with milder symptoms (within the label-indicated population)
- Impact on reduced/ delayed need for surgery
- Impact on the quality of life
- Adjustment of background therapy (beta-blockers, calcium-channel blockers, ARBs)
*Interventional and observational projects are acceptable, including new approaches to real-world data.
Out of Scope:
Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.
Implementation of best practices
In Scope:
- Decision-making support to include patient-preference
- Approaches to improve patient and provider experience with CAMZYOS
*Interventional and observational projects are acceptable, including new approaches to real-world data.
Out of Scope:
Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here